|Last Price$263.66||Day Change (%)-1.24%|
|Open Price$265.79||Day Change ($)-3.31|
|Day Range263.49–269.78||52-Week Range107.31–283.99|
As of Mon 05/20/2013 04:19 PM EDT | USD
Regeneron Pharmaceuticals Co-Founder Receives $81.55 Million Compensation
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
Good morning, ladies and gentlemen. Welcome to the Regeneron Pharmaceuticals' Conference Call to discuss the Fourth Quarter and Year End 2012 Financial Results. My name is Bethany, and I'll be your coordinator today. At this time all participants are in a listen-only mode. We will conduct a ...
Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
Regeneron Reports First Quarter 2013 Financial and Operating Results
BioMed Realty Trust Reports First Quarter 2013 Financial Results
Regeneron Set to Join the S&P 500; Eagle Materials, CST Brands to Join the S&P MidCap 400; Francesca's, Northern Oil & Gas to Join the S&P SmallCap 600
U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
Regeneron to Join S&P 500 After MetroPCS Merger with T-Mobile
As part of Aberdeen's acquisition of Artio, some international fund managers to depart. Also, a management change on a T. Rowe Price health-care fund, Columbia hires Putnam's former asset-allocation head, and ClearBridge and Legg Mason Capital Management funds to merge.